AFP and hepatocellular carcinoma: Although many biomarkers areas provide the diagnosis and prognosis of HCC, such as alpha-fetoprotein (AFP), osteopontin, their clinical value is limited, and the 5-year survival rate of HCC patients is still bad, so urgently need a new and effective therapeutic prognostic biomarker or target to predict or reduce the recurrence and death of HCC [22].